Neonc Technologies President Buys 10,000 Shares

Amir Heshmatpour increases stake in biotech company amid stock volatility

Apr. 11, 2026 at 11:18am

Got story updates? Submit your updates here. ›

An extreme close-up photograph of complex, highly engineered biotech laboratory equipment, conveying a sense of scientific innovation and technological advancement without any text or identifying marks.Neonc Technologies' insider buying signals potential confidence in the company's biotech pipeline, despite recent stock volatility.Los Angeles Today

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) President Amir Heshmatpour acquired 10,000 shares of the company's stock on April 10th, increasing his total ownership to over 3 million shares. The transaction, valued at $48,900, represents a 0.33% increase in Heshmatpour's position.

Why it matters

Insider buying activity can be a signal of management's confidence in a company's future prospects, especially during periods of market volatility. Neonc Technologies is a clinical-stage biotech developing novel treatments for central nervous system diseases, and this purchase by the company president may indicate optimism about the firm's pipeline and growth potential.

The details

Heshmatpour's purchase of 10,000 Neonc Technologies shares was made at an average price of $4.89 per share. Following the transaction, the president now directly owns 3,042,000 shares of the company's stock, valued at approximately $14.9 million based on the current share price.

  • The share acquisition took place on Friday, April 10, 2026.
  • Neonc Technologies' stock has traded between $3.20 and $12.99 over the past 52 weeks, with the 50-day moving average at $8.56 and the 200-day moving average at $9.07.

The players

Amir Heshmatpour

President of Neonc Technologies Holdings, Inc., a clinical-stage biotech company developing novel treatments for central nervous system diseases.

Neonc Technologies Holdings, Inc.

A biotech company focused on developing enhanced targeted delivery technologies for treating central nervous system diseases, including glioblastoma and other conditions.

Got photos? Submit your photos here. ›

What’s next

Investors will likely monitor Neonc Technologies' stock performance and any further insider buying or selling activity as the company advances its clinical pipeline.

The takeaway

Insider buying by Neonc Technologies' president during a period of market volatility suggests management confidence in the company's long-term growth prospects, even as the stock has experienced significant price swings recently.